Although treatments of hypertension have significantly decreased morbidity and mortality from cerebrovascular disease, the associated reductions in coronary artery disease have been very disappointing. Hypertension is a complex inherited syndrome of cardiovascular risk factors, all of which contribute to the development of heart disease. Angiotensin II receptor blockers (ARBs), such as the highly selective ARB valsartan, provide an alternative treatment strategy to address the multiple issues in coronary artery disease. These agents are welltolerated and have a once-daily regimen that improves compliance. They bring multiple cardiovascular benefits beyond blood pressure (BP) control, such as renoprotection and cardiovascular growth reduction.
Introduction
The recognition of hypertension as a disease process came from epidemiological studies showing that patients with high blood pressure (BP) had an increased incidence of stroke and heart attack. The real goal in the treatment of hypertension is to reduce the incidence of cardiovascular events to that seen in normotensive subjects.
A meta-analysis of antihypertensive therapy shows that there has been an encouraging 48% reduction in the incidence of stroke, but only a 16% reduction in the incidence of coronary artery disease, which is far less than that predicted by epidemiological studies. 1 This suggests a need for change in the management of hypertension. This paper discusses a number of problems that contribute to this lack of impact on the incidence of heart attack in hypertensive patients.
Inadequate control of hypertension
There are alarming statistics on hypertension from the National Health and Nutrition Examination Survey (NHANES) ( Table 1 ). 2 If the standard for adequate control of hypertension is taken as 140/90 mmHg,only one quarter of the hypertensive patients in the US are adequately controlled.This figure does not take into account hypertensive people over the age of 75; including that part of the population reduces the proportion with adequate BP control to about 16%.
These figures are mirrored by statistics from other countries around the world. Reports from Scotland, Germany, Spain, Australia and Canada all show a similar lack of control of hypertension. 3 This poor control contributes significantly to a minimal effect on coronary artery disease, as it has been shown that inadequately controlled hypertension remains a significant risk factor for coronary artery disease.
Hypertensive patients receiving treatment may still not be adequately controlled. Figures from the United States show that only 54% of men and 48% of women who are seeing a physician and receiving treatment have adequately controlled hypertension. 4 The same is seen in other countries (Table 2) , 3 implying a general tendency for physicians to accept inadequate BP control in hypertensives on treatment.
Treated hypertensive patients who are inadequately controlled remain at a significant risk for developing heart disease. The Multiple Risk Factor Intervention Trial (MRFIT) study 5 showed that the highest incidence of cardiovascular disease in hypertensive patients occurred in those with systolic BP between 130-160 mmHg, which was the typical systolic BP range in inadequately controlled hyperten- 
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December 2000 Volume 1 Supplement 2 S11 sive patients on treatment ( Figure 1 ). Therefore, simply treating BP is not enough; target blood levels must be achieved in order to have an impact on coronary artery disease.
Treatment makes a difference
Relatively small reductions in BP can make a significant difference in terms of mortality and morbidity. The United Kingdom Prospective Diabetes Study (UKPDS) researchers divided their study population into a tight BP-control group (mean BP over nine years 144/82 mmHg) and a less tight BP-control group (mean BP 154/87 mmHg). 6 Although the difference between the two groups was only 10/5 mmHg, there were statistically significant benefits from tightly controlling BP, including a 32% reduced risk of diabetes-related death (p=0.019) and a 44% reduced risk of stroke (p=0.013). This shows that aggressive treatment of hypertension can have dramatic effects on rates of cardiovascular events. This is particularly true in diabetic patients.
Although studies such as the UKPDS study and the HOT study have clearly demonstrated that tight blood pressure control is associated with a decrease in cardiovascular mortality and morbidity world wide, BP levels are still very disappointing. Thus, in order to improve cardiovascular events in hypertensive patients, it is important to establish why we are not controlling BP. There are obviously several reasons for poor BP control, but amongst the most important which can be influenced by physicians are the following:
The importance of compliance
Poor patient compliance with antihypertensive therapy still remains the most important reason for inadequate BP control. Compliance generally depends on two factors: • the convenience of dosing • the incidence of side-effects.
ARBs represent an important addition to our management of hypertension with regard to patient compliance. This class of drug is extraordinarily well-tolerated and has a side-effect profile that is as good as placebo even at the highest doses ( Figure  2 ). 7, 8 In addition, the newer ARB's have been shown with ambulatory blood pressure monitoring (ABPM) to provide effective BP control throughout the dosing interval, including the period during arousal from sleep. 9 Thus, ARBs, more than any other class of antihypertensive therapy, seem to provide the safety and convenience that can influence compliance rates. Data from a large pharmacological database in the US show that, after one year of therapy, 72% of patients taking ARBs remain compliant, whereas the figures for ACE inhibitors, calcium channel blockers and diuretics are 61%, 61% and 59%, respectively. 10
Hypertension and combination therapy
As hypertension is a multifactorial disease, over 50% of patients are unable to be adequately controlled with monotherapy. The use of low-dose combination therapy, either as first-line treatment or early in management, may be a very important change required in our approach to managing hypertension that may help to improve BP control rates. For example, the addition of 12.5 mg of hydrochlorothiazide to ARBs results in a significant improvement in BP control rates without having a negative impact on the adverse effect profile. 11
The importance of systolic blood pressure
It is now known that systolic blood pressure (SBP) is a better predictor of cardiovascular events than DBP, as was clearly demonstrated by a re-analysis of the MRFIT database. 12 ARBs are very useful in the reduction of SBP. A recent study shows impressive reductions in SBP, in elderly patients with isolated systolic hypertension following valsartan therapy (Figure 3 ). 8 This is important in terms of reducing pulse pressure. Valsartan is also very well-tolerated, which is particularly important in these older hypertensive patients. at SAGE Publications on June 21, 2016 jra.sagepub.com Downloaded from S12 A complex syndrome of cardiovascular risk factors Treated hypertensive patients with BP controlled to 120/80 mmHg who are matched with normotensives for age, weight and body mass index, are still at a higher risk of coronary artery disease. 13 This suggests that there are additional risk factors to BP for this disease process.
It is now known that hypertension is a complex syndrome of cardiovascular risk factors, all of which occur more commonly in hypertensive patients than in normotensives and which may even precede the onset of high BP (Figure 4 ). These may be inherited and contribute to coronary artery disease, independently of BP.
Atherosclerosis
A number of vascular changes lead to the development of atherosclerosis. Endothelial dysfunction allows entrance of low-density lipoprotein (LDL) particles into the sub-intimal space with subsequent development of foam cells and fatty streaks. A decrease in arterial compliance, leading to stiffening of the artery, is also connected with the development of atherosclerosis.
Studies have demonstrated that the most dramatic changes to arterial compliance, both in the proximal and distal vessels, occur early in the course of the disease process and prior to the onset of high blood pressure. These changes are probably mediated by inherited endocrine and neurohormonal changes that alter vascular structure and function and result in the development of atherosclerosis and an increase in BP.
A number of factors such as smoking, increased LDL-cholesterol and raised Ang II levels, all lead to endothelial dysfunction over time. Studies have shown that endothelial dysfunction occurs as a result of an imbalance between NO and Ang II levels in the endothelial cells. Imbalance in favour of Ang II results in endothelial dysfunction and its consequences. As a result, the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the development of atherosclerotic disease.
ARBs work by blocking AT 1 -receptors to the effect of Ang II on endothelial cells, thus restoring the balance between NO and Ang II and so may reverse or prevent endothelial disease and atherosclerosis. This has been shown in cholesterol-fed rabbits where valsartan, 3 mg/kg or 10 mg/kg, clearly prevents the progression of atherosclerosis. 14
Conclusion
It is thus becoming clear that the disappointing reduction in the incidence of coronary artery disease in treated hypertensives is a result both of inadequate BP control and the fact that we are not treating hypertension as a multifactorial syndrome. Our selection of drugs for the management of these patients will be crucial in improving these findings. Our focus should be on selecting drugs that reduce BP, but that also have a positive, or at least a neutral, effect on other cardiovascular risk factors. In addition, we should aggressively manage other cardiovascular risk factors in hypertensive patients, as it has been shown that they are synergistic in their ability to cause heart disease. This comprehensive approach is likely to result in a greater impact on cardiovascular disease in hypertensive patients. Over the next few years, physicians will need to target therapy more specifically to ensure they use drugs that not only reduce BP, but that are also beneficial in terms of other cardiovascular risk factors. Only then will there be a reduction in the incidences of coronary artery disease. 
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